Tracking when private companies are nearing a sale, recap, or financing event has always been a guessing game. With thousands of sponsor-backed firms spread across sectors and geographies, most deal teams are forced to react after the market moves.
Investors, bankers, and service providers struggle to know which private companies are gearing up for a transaction or capital raise. Signals are scattered, opaque, and nearly impossible to track across thousands of PE- and VC-backed businesses.
Dakota centralizes those signals (holding periods, funding rounds, platform acquisition dates, ownership changes, and exit timing patterns) into one predictive transaction-readiness tool. Instead of waiting for headlines, users can see which companies are showing the strongest likelihood of pursuing a sale, recapitalization, or new financing before the market knows.
Below is today’s list of five PE- or VC-backed companies that, based on their hold period, financing stage, and last transaction date, appear to be credible candidates for a sale or next-round raise.
Nothing is guaranteed, but these companies fall squarely within the timing windows where sponsors typically look to generate liquidity or secure additional capital.
Sourced from Dakota Sponsor Backed Companies.
1. Intellicar
Intellicar Telematics is an Indian technology company specializing in Internet of Things (IoT) solutions for the automotive and electric vehicle (EV) sectors. Founded in 2015 and headquartered in Bengaluru, Karnataka, India, the company offers a comprehensive suite of services, including telematics, fleet management, fuel monitoring, keyless access control, driver and passenger safety, driver coaching, preventive maintenance, and predictive analytics. Their mission is to build a technology suite that enables the sensorization of any asset, mobile or stationary, to capture valuable data for business-critical decisions.
- Sector: IoT / Mobility Tech / EV Infrastructure
- Last known transaction date: Series A $13.5M
- Why timing suggests a near-term transaction: The company recently raised a meaningful Series A round backed by Nuveen’s Private Equity Impact strategy, providing institutional validation and typically implying a 2–4 year window for a follow-on raise or exit. The capital is being deployed to scale its data and energy solutions and expand into new markets, which generally precedes strong growth milestones and additional fundraising activity. Intellicar is also benefiting from strong secular tailwinds, as it operates at the intersection of EV adoption, fleet digitization, and emissions reduction—areas that continue to attract significant private equity and growth capital interest. The business has already achieved meaningful scale, serving over 300,000 EVs, positioning it as an attractive target for future growth equity investment or strategic acquisition. Additionally, backing from a large global asset manager focused on impact and climate solutions suggests a clear pathway toward larger follow-on rounds or a strategic exit within the EV ecosystem.
View all private company data in Dakota Marketplace.
2. Grove Biopharma, Inc.
Grove Biopharma is a Chicago-based biotechnology company pioneering Bionic Biologics™, a novel therapeutic modality targeting intracellular protein-protein interactions. Their proprietary platform integrates biologic and synthetic design principles to develop cell-permeable, customizable therapeutics aimed at treating diseases such as cancer, neurodegenerative disorders, and rare conditions.
- Sector: Health Care
- Last known transaction date: Series A Venture, $30M, April 2025
- Why timing suggests a near-term transaction: A $30M Series A in April 2025 is a deliberately rightsized raise for a preclinical biopharma — Grove's CEO acknowledged they originally targeted $50M — meaning the capital will be consumed advancing lead oncology programs toward an IND submission, with the 18–24 month preclinical-to-clinic timeline pointing to a Series B conversation becoming relevant in late 2026 to early 2027.
View all private company data in Dakota Marketplace.
3. Synthetic Design Lab
Synthetic Design Lab is a biotechnology company founded in 2021, headquartered in San Carlos, California. The company specializes in developing next-generation antibody-drug conjugates (ADCs) through its proprietary SYNTHBODY™ therapeutic platform, aiming to enhance the efficacy, safety, and versatility of ADCs in cancer treatment. The leadership team includes CEO and Founder Dr. Daniel S. Chen, a pioneer in cancer immunotherapy and protein engineering, and Chief Scientific Officer Dr. Ramesh Baliga, who brings over 25 years of experience in biotechnology.
- Sector: Health Care
- Last known funding round: Seed Venture, $20M, April 2025
- Why timing suggests a near-term transaction: Having emerged from stealth with a $20M seed in April 2025 and a stated goal of entering clinical trials in 2026, Synthetic Design Lab is on a compressed timeline where seed capital will be consumed advancing its SYNTHBODY platform toward IND — with the 18–24 month preclinical-to-clinic runway pointing to a Series A conversation becoming relevant in late 2026 to early 2027.
View all private company data in Dakota Marketplace.
4. Neurolabs
Neurolabs is a London-based company specializing in computer vision solutions for the consumer packaged goods (CPG) sector. Their flagship product, ZIA, leverages synthetic image recognition to enhance retail execution, offering features like catalogue management, real-time insights, and workflow automation. By utilizing synthetically generated data, Neurolabs provides cost-effective and rapid deployment of advanced computer vision applications, enabling businesses to optimize their retail operations.
- Sector: Information Technology
- Last known funding round: Series A Venture, $7.8M, April 2025
- Why timing suggests a near-term transaction: A $7.8M Series A in April 2025 represents a relatively lean raise for a company scaling an AI-driven enterprise platform, particularly as Neurolabs continues to invest in product development and go-to-market expansion. Given the capital-intensive nature of building and deploying computer vision solutions for large CPG customers, this funding is likely to be consumed relatively quickly as the company scales its engineering team and commercial footprint. As a result, Neurolabs is likely to require additional capital within a typical 12–18 month post-close window, positioning it for a Series B raise in mid-to-late 2026, especially if it demonstrates traction with enterprise customers and continued product adoption.
View all private company data in Dakota Marketplace.
5. RepAir Carbon
RepAir Carbon is a pioneering company specializing in carbon dioxide removal (CDR) technologies, focusing on scalable and efficient solutions to combat climate change. Their innovative electrochemical process captures CO₂ from both ambient air and industrial point sources, offering a sustainable approach to achieving gigaton-scale carbon removal.
- Sector: Climate Tech / Carbon Capture (CDR)
- Last known funding round: Series A Extension, $15M (+ $3M non-dilutive grant), April 2025
- Why timing suggests a near-term transaction: RepAir Carbon’s $15M Series A extension in April 2025 is positioned to fund the transition from technology development to early commercial-scale deployment, including manufacturing scale-up and demonstration projects with industrial partners. Given the capital-intensive nature of carbon capture infrastructure and the company’s focus on scaling engineering and production capabilities, this funding is likely to be deployed rapidly as it moves toward commercialization. Additionally, the carbon removal market remains early and highly dependent on project financing and strategic partnerships, increasing the need for follow-on capital as projects mature. As RepAir advances pilot deployments and commercial validation, it will likely require additional growth capital within a typical 12–24 month window, positioning the company for a Series B or project-linked financing in 2026 to 2027.
View all private company data in Dakota Marketplace.
Use Dakota’s Sponsor Backed Company Intelligence to Spot Likely Exits Before the Market Does
Dakota’s private company data gives you a real-time view into thousands of sponsor-backed companies, including platform acquisition dates, funding rounds, parent sponsors, add-on activity, and sector categorization.
Instead of guessing where companies are in their lifecycle, you can instantly identify which ones are approaching the typical timing windows for a sale or recap.
Fully integrated into Dakota Marketplace, this dataset enables deal sourcers, investor relations teams, and allocators to anticipate transactions, build targeted outreach lists, and stay ahead of market announcements, every single day.
To explore more companies likely to transact, book a demo of Dakota Marketplace!
